image
Pacira BioSciences, Inc. PCRX
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
Watchlist
$ 25.18
-2.56 %
$ 1.17 B
Market Cap
-11.7
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one PCRX stock under the worst case scenario is HIDDEN Compared to the current market price of 25.2 USD, Pacira BioSciences, Inc. is HIDDEN

PCRX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one PCRX stock under the base case scenario is HIDDEN Compared to the current market price of 25.2 USD, Pacira BioSciences, Inc. is HIDDEN

PCRX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one PCRX stock under the best case scenario is HIDDEN Compared to the current market price of 25.2 USD, Pacira BioSciences, Inc. is HIDDEN

PCRX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart PCRX

image
1M 2%
6M 52%
1Y -22%
3Y -153%
5Y -79%
All
$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
701 M REVENUE
3.85%
Growth Rates
1Year 3.85%
3Years 8.98%
5Years 10.73%
7Years 13.63%
10Years 13.49%
-73.4 M OPERATING INCOME
-83.69%
Growth Rates
1Year -83.69%
3Years -15.97%
5Years -23.95%
7Years -16.67%
10Years -30.39%
-99.6 M NET INCOME
-237.30%
Growth Rates
1Year -237.30%
3Years -49.95%
5Years -55.31%
7Years -12.89%
10Years -21.92%
189 M OPERATING CASH FLOW
22.46%
Growth Rates
1Year 22.46%
3Years 14.64%
5Years 21.85%
7Years 40.20%
10Years 22.22%
-83.3 M INVESTING CASH FLOW
-107.40%
Growth Rates
1Year -107.40%
3Years -58.81%
5Years 8.31%
7Years 13.17%
10Years 3.53%
17.4 M FINANCING CASH FLOW
109.49%
Growth Rates
1Year 109.49%
3Years -64.27%
5Years 36.46%
7Years -30.61%
10Years -17.50%
187 M REVENUE
11.08%
Growth Rates
1Year 3.85%
3Years 8.98%
5Years 10.73%
7Years 13.63%
10Years 13.49%
24.7 M OPERATING INCOME
117.71%
Growth Rates
1Year -83.69%
3Years -15.97%
5Years -23.95%
7Years -16.67%
10Years -30.39%
16 M NET INCOME
111.18%
Growth Rates
1Year -237.30%
3Years -49.95%
5Years -55.31%
7Years -12.89%
10Years -21.92%
33.1 M OPERATING CASH FLOW
-38.55%
Growth Rates
1Year 22.46%
3Years 14.64%
5Years 21.85%
7Years 40.20%
10Years 22.22%
-368 K INVESTING CASH FLOW
99.29%
Growth Rates
1Year -107.40%
3Years -58.81%
5Years 8.31%
7Years 13.17%
10Years 3.53%
-1.96 M FINANCING CASH FLOW
31.28%
Growth Rates
1Year 109.49%
3Years -64.27%
5Years 36.46%
7Years -30.61%
10Years -17.50%
Balance Sheet Pacira BioSciences, Inc.
image
Current Assets 745 M
Cash & Short-Term Investments 485 M
Receivables 113 M
Other Current Assets 147 M
Non-Current Assets 808 M
Long-Term Investments 0
PP&E 216 M
Other Non-Current Assets 592 M
31.19 %7.29 %9.48 %13.93 %38.11 %Total Assets$1.6b
Current Liabilities 310 M
Accounts Payable 19.1 M
Short-Term Debt 211 M
Other Current Liabilities 80.1 M
Non-Current Liabilities 465 M
Long-Term Debt 428 M
Other Non-Current Liabilities 37.1 M
27.18 %10.34 %55.24 %4.78 %Total Liabilities$775.2m
EFFICIENCY
Earnings Waterfall Pacira BioSciences, Inc.
image
Revenue 701 M
Cost Of Revenue 170 M
Gross Profit 531 M
Operating Expenses 604 M
Operating Income -73.4 M
Other Expenses 26.2 M
Net Income -99.6 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)701m(170m)531m(604m)(73m)(26m)(100m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.69% GROSS MARGIN
75.69%
Averages
1Year 75.69%
3Years 72.81%
5Years 72.93%
7Years 73.37%
10Years 71.42%
-10.47% OPERATING MARGIN
-10.47%
Averages
1Year -10.47%
3Years 3.84%
5Years 9.35%
7Years 8.64%
10Years 4.40%
-14.20% NET MARGIN
-14.20%
Averages
1Year -14.20%
3Years -1.87%
5Years 7.35%
7Years 4.85%
10Years 0.61%
-12.79% ROE
-12.79%
Averages
1Year -12.79%
3Years -1.97%
5Years 4.66%
7Years 2.87%
10Years -1.17%
-6.41% ROA
-6.41%
Averages
1Year -6.41%
3Years -0.93%
5Years 2.13%
7Years 1.32%
10Years -0.67%
-7.96% ROIC
-7.96%
Averages
1Year -7.96%
3Years 0.19%
5Years 6.82%
7Years 6.03%
10Years 3.10%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pacira BioSciences, Inc.
image
180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -99.6 M
Depreciation & Amortization 78.8 M
Capital Expenditures -10.6 M
Stock-Based Compensation 51.2 M
Change in Working Capital 0
Others 138 M
Free Cash Flow 179 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pacira BioSciences, Inc.
image
Wall Street analysts predict an average 1-year price target for PCRX of $30 , with forecasts ranging from a low of $8 to a high of $57 .
PCRX Lowest Price Target Wall Street Target
8 USD -68.23%
PCRX Average Price Target Wall Street Target
30 USD 19.14%
PCRX Highest Price Target Wall Street Target
57 USD 126.37%
Price
Max Price Target
Min Price Target
Average Price Target
6060555550504545404035353030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Pacira BioSciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
26.1 K USD 2
6-9 MONTHS
6.43 K USD 1
9-12 MONTHS
621 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
32.8 K USD 2
6-9 MONTHS
183 K USD 4
9-12 MONTHS
7. News
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings. zacks.com - 2 weeks ago
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis BRISBANE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis of the knee. globenewswire.com - 2 weeks ago
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 BRISBANE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter financial results after the close of the U.S. markets on Thursday May 8, 2025. globenewswire.com - 3 weeks ago
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee -- PCRX-201 demonstrated two years of clinically meaningful improvements in pain, stiffness and function across all structural severity subgroups, including advanced disease -- -- Study Findings Presented at 2025 OARSI World Congress-- BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data demonstrating its locally administered gene therapy candidate, PCRX-201 (enekinragene inzadenovec), provided sustained improvements in knee pain, stiffness, and function for up to two years following a single local administration in patients with mild, moderate, as well as severe osteoarthritis of the knee. globenewswire.com - 3 weeks ago
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee -- Poster to be presented at OARSI World Congress on Osteoarthritis -- BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the upcoming presentation of new 104-week data in support of its locally administered gene therapy candidate, PCRX-201 (enekinragene inzadenovec). The data is being presented at the 2025 Osteoarthritis Research Society International (OARSI) World Congress in Incheon, South Korea, April 24-27. globenewswire.com - 4 weeks ago
Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 4 weeks ago
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History MIAMI , April 21, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ:  PCRX ) ("Pacira" or the "Company"). Following constructive engagement with Pacira, DOMA Perpetual believes the Company's new capital allocation announcementi represents the Board's firm commitment to enhancing shareholder value. prnewswire.com - 4 weeks ago
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRA. accessnewswire.com - 1 month ago
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders -- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan – globenewswire.com - 1 month ago
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval. globenewswire.com - 1 month ago
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX's PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM. seekingalpha.com - 1 month ago
PCRX Stock Soars on Exparel Patent Settlement With Generic Players Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030. zacks.com - 1 month ago
8. Profile Summary

Pacira BioSciences, Inc. PCRX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.17 B
Dividend Yield 0.00%
Description Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Contact 5401 West Kennedy Boulevard, Tampa, FL, 33609 https://www.pacira.com
IPO Date Feb. 3, 2011
Employees 788
Officers Mr. Anthony Molloy III, Esq. Chief Legal & Compliance Officer Ms. Kristen Williams Esq., J.D. Chief Administrative Officer & Secretary Mr. Christopher C. Young Chief Manufacturing Officer Dr. Jonathan Slonin M.D. Chief Medical Officer Mr. David M. Stack Advisor Mr. Charles A. Reinhart III, CPA, M.B.A. Executive Officer Ms. Susan Mesco Head of Investor Relations Mr. Frank D. Lee Chief Executive Officer & Director Mr. Shawn M. Cross Chief Financial Officer Ms. Lauren Bullaro Riker Principal Accounting Officer & Senior Vice President of Finance